5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic

Class

Sublingual formulation of cyclobenzaprine, a tricyclic-structure multi-receptor CNS antagonist; mechanism for its approved fibromyalgia indication is not fully established despite the receptor-binding profile being characterized

Pathway

Multi-receptor CNS modulation (serotonergic, adrenergic, histaminergic, cholinergic)

Notes

original target text: 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)

This mechanism describes a small molecule with a tricyclic chemical backbone, structurally related to older antidepressants, that acts as a functional antagonist at four distinct receptor types: the serotonin 5-HT2A receptor, the α1-adrenergic receptor, the histamine H1 receptor, and the muscarinic M1 acetylcholine receptor. Rather than targeting a single pathway, this compound dampens signaling across serotonergic, adrenergic, histaminergic, and cholinergic systems simultaneously. Each of these receptors normally participates in regulating arousal, vascular tone, wakefulness, and smooth muscle or central excitability. Blocking them together produces sedation, muscle relaxation, and reduced central nervous system excitability, which is the rationale historically used for treating muscle spasm and, in some contexts, chronic widespread pain conditions such as fibromyalgia. However, exactly how this broad receptor-blocking profile translates into relief of fibromyalgia symptoms is not firmly established mechanistically, even though the individual receptor interactions are well characterized. This class of multi-receptor antagonism sits between antidepressants and muscle relaxants pharmacologically, and its therapeutic effects likely arise from combined sedative, anti-nociceptive, and central relaxant properties rather than from a single well-defined molecular pathway.